The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung

[1]  H. Hansen,et al.  Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines. , 1987, European journal of cancer & clinical oncology.

[2]  H. Hansen,et al.  Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Leyland-Jones,et al.  Teniposide: a review of 12 years of experience. , 1984, Cancer treatment reports.

[4]  H. Hansen,et al.  Phase II study of teniposide in small cell carcinoma of the lung. , 1984, Cancer treatment reports.

[5]  B. Hill,et al.  Establishment of an etoposide‐resistant human epithelial tumour cell line In vitro: Characterization of patterns of cross‐resistance and drug sensitivities , 1984, International journal of cancer.

[6]  H. Hansen,et al.  Etoposide (VP-16) in the treatment of lung cancer. , 1983, Cancer treatment reviews.

[7]  W. Evans,et al.  Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts. , 1983, Cancer research.

[8]  N. Keiding,et al.  Long-term storage of samples for flow cytometric DNA analysis. , 1983, Cytometry.

[9]  I. Christensen,et al.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. , 1983, Cytometry.

[10]  R. Gupta.  Podophyllotoxin-resistant mutants of Chinese hamster ovary cells: cross-resistance studies with various microtubule inhibitors and podophyllotoxin analogues. , 1983, Cancer research.

[11]  I. Tannock,et al.  A critical appraisal of the "human tumor stem-cell assay". , 1983, The New England journal of medicine.

[12]  B. Hill,et al.  AN EXPERIMENTAL BIOLOGICAL BASIS FOR INCREASING THE THERAPEUTIC INDEX OF CLINICAL CANCER THERAPY , 1982, Annals of the New York Academy of Sciences.

[13]  P. Creaven.  The clinical pharmacology of VM26 and VP16-213 , 1982, Cancer Chemotherapy and Pharmacology.

[14]  L. Allen.  Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell. , 1978, Cancer research.

[15]  D. V. Von Hoff,et al.  VM 26 and VP 16–213: A comparative analysis , 1977, Cancer.

[16]  P. Creaven,et al.  Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives. , 1975, European journal of cancer.

[17]  O. Selawry,et al.  Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213). , 1974, Cancer chemotherapy reports.

[18]  L. Putten,et al.  ARE CELL KINETIC DATA RELEVANT FOR THE DESIGN OF TUMOUR CHEMOTHERAPY SCHEDULES? * , 1974 .

[19]  H. Stähblin,et al.  Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. , 1973, European journal of cancer.

[20]  Hansen Hh,et al.  Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819). , 1971 .

[21]  S. Salmon,et al.  Antitumor activity of didemnin B in the human tumor stem cell assay , 2004, Cancer Chemotherapy and Pharmacology.

[22]  L. V. van Putten,et al.  Are cell kinetic data relevant for the design of tumour chemotherapy schedules? , 1974, Cell and tissue kinetics.

[23]  H. Stähelin.  Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. , 1973, European journal of cancer.

[24]  H. Hansen,et al.  Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819). , 1971, Cancer chemotherapy reports.